IRIS
BLANDINI, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.030
AS - Asia 4.284
EU - Europa 3.050
SA - Sud America 670
Continente sconosciuto - Info sul continente non disponibili 214
AF - Africa 202
OC - Oceania 13
Totale 15.463
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.846
CN - Cina 1.545
SG - Singapore 1.069
IE - Irlanda 979
HK - Hong Kong 701
BR - Brasile 498
VN - Vietnam 409
RU - Federazione Russa 397
DE - Germania 333
FI - Finlandia 251
FR - Francia 221
IT - Italia 219
UA - Ucraina 208
GB - Regno Unito 130
ZA - Sudafrica 123
IN - India 103
CA - Canada 99
SE - Svezia 87
BD - Bangladesh 72
JP - Giappone 62
IQ - Iraq 50
AR - Argentina 49
MX - Messico 48
PK - Pakistan 39
CZ - Repubblica Ceca 38
TR - Turchia 36
ID - Indonesia 30
ES - Italia 29
CO - Colombia 28
PL - Polonia 26
EC - Ecuador 24
SA - Arabia Saudita 24
BE - Belgio 23
NL - Olanda 21
AT - Austria 20
LT - Lituania 19
CL - Cile 17
VE - Venezuela 16
PY - Paraguay 15
UZ - Uzbekistan 15
MA - Marocco 14
MU - Mauritius 14
PH - Filippine 14
JO - Giordania 12
AU - Australia 11
PE - Perù 11
TN - Tunisia 11
EG - Egitto 10
AZ - Azerbaigian 9
MY - Malesia 9
DO - Repubblica Dominicana 8
AE - Emirati Arabi Uniti 7
KZ - Kazakistan 7
IL - Israele 6
KE - Kenya 6
KG - Kirghizistan 6
UY - Uruguay 6
CH - Svizzera 5
CR - Costa Rica 5
KR - Corea 5
LB - Libano 5
NP - Nepal 5
SN - Senegal 5
AL - Albania 4
BH - Bahrain 4
BO - Bolivia 4
CY - Cipro 4
ET - Etiopia 4
GT - Guatemala 4
HR - Croazia 4
IS - Islanda 4
PA - Panama 4
RS - Serbia 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
AM - Armenia 3
BN - Brunei Darussalam 3
EE - Estonia 3
EU - Europa 3
HN - Honduras 3
JM - Giamaica 3
KH - Cambogia 3
LV - Lettonia 3
NG - Nigeria 3
OM - Oman 3
PS - Palestinian Territory 3
PT - Portogallo 3
RO - Romania 3
BG - Bulgaria 2
BY - Bielorussia 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
IR - Iran 2
KW - Kuwait 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LY - Libia 2
MR - Mauritania 2
Totale 15.221
Salva come PNG Salva come JPEG
Città #
Chandler 1.008
Dublin 979
San Jose 816
Ashburn 703
Hong Kong 687
Dallas 520
Singapore 501
Beijing 400
Jacksonville 254
Boardman 231
Princeton 190
Lawrence 186
Council Bluffs 179
Nanjing 177
Los Angeles 166
Lauterbourg 162
Medford 152
Ho Chi Minh City 144
Wilmington 136
Helsinki 116
New York 113
Hanoi 107
Johannesburg 101
Shanghai 89
Munich 86
Santa Clara 81
Redondo Beach 79
Nanchang 77
Buffalo 72
Shenyang 69
Changsha 62
São Paulo 61
Tokyo 58
Chicago 56
Moscow 56
Toronto 51
The Dalles 50
Tianjin 47
Hebei 45
Ann Arbor 43
Jiaxing 42
Milan 41
Orem 39
Pavia 37
Brno 32
Columbus 32
Chennai 31
Hangzhou 31
Norwalk 31
San Francisco 31
Brooklyn 30
Frankfurt am Main 27
Washington 26
Turku 25
Brussels 23
Denver 21
London 21
Montreal 21
Stockholm 21
Warsaw 21
Da Nang 20
Falkenstein 20
Nuremberg 20
Mexico City 19
Seattle 19
Atlanta 18
Baghdad 18
Boston 18
Manchester 18
Guangzhou 17
Phoenix 17
Piscataway 17
Fairfield 16
Lahore 16
Düsseldorf 14
New Delhi 14
Rio de Janeiro 14
Woodbridge 14
Haiphong 13
Philadelphia 13
Tashkent 13
Amsterdam 12
Belo Horizonte 12
Houston 12
Rome 12
Amman 11
Des Moines 11
Elk Grove Village 11
Medellín 10
Paris 10
Santiago 10
Vienna 10
Ankara 9
Baku 9
Cairo 9
Can Tho 9
Poplar 9
Riyadh 9
Shijiazhuang 9
Wuhan 9
Totale 10.234
Salva come PNG Salva come JPEG
Nome #
Correlation of LTP and LTD with gene expression in the cerebellar cortex. 177
Alterazioni neurochimiche del sistema nervoso enterico (SNE) in un modello sperimentale di Parkinson 163
Acute Reduction of Anandamide-Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medication-Overuse Headache Subjects After Withdrawal Treatment. 158
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model 151
A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. 147
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 144
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 144
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells 143
Immediate early genes regulation in rat cerebellar cortex during long-term synaptic plasticity induction. 134
Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. 133
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 132
Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: Relevance to gastrointestinal dysfunctions in Parkinson's disease 131
Activation of the CREB/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer 130
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats 125
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 125
Aging and dementia: markers of the hypothalamus-pituitary-adrenal axis and sympathetic activities in biological fluids 121
Long-term synaptic plasticity and related gene expression in the cerebellar cortex. 119
Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self perpetuating crosstalk? 118
Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: Potential relevance to the pathophysiology of Parkinson's disease 117
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 115
Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease 115
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease 112
Stress and Autonomic Nervous System 111
Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemia-reperfusion injury 111
Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: Potential targets for a new therapeutic approach 110
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease 106
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations 106
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 103
Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease 103
Functional changes of the basal ganglia circuitry in Parkinson's disease. 101
A reliable indirect cell-labelling protocol for optical imaging allows ex vivo visualisation of mesenchymal stem cells after transplantation 100
A 2A receptor antagonism and dyskinesia in parkinson's disease 100
In vivo imaging of early signs of dopaminergic neuronal death in an animal model of Parkinson's disease 99
Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease 99
Pro-oxidant activity and methionine metabolism in chronic alcohol abusers: relationship to alcohol withdrawal and folate administration 99
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 98
Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson's Disease 98
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 97
Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine 97
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. 96
Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease 96
Naproxen Sodium in Menstrual Migraine Prophylaxis: A Double‐Blind Placebo Controlled Study 96
Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease 95
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 95
Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects 95
Repurposing opportunities for Parkinson’s disease therapies 95
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease 95
Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat 94
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity 94
Cardiopressor effects of short-term treatment with cabergoline in L-Dopa stable responder parkinsonian patients: Relevance of postprandial hypotension 94
Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer's disease 94
Parkinson's disease patients have a complex phenotypic and functional Th1 bias: Cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients 93
Fibroblasts from skin biopsies as a tool for biomarker discovery in Parkinson׳s disease 93
The role of dopamine in the modulation of gastrointestinal motility in a rat model of Parkinson's disease 92
Mitochondrial Complex i Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease 92
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease 92
Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors 92
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 92
Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease 92
Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine 90
Rationale and design of the CV-PREVITAL study: an Italian multiple cohort randomised controlled trial investigating innovative digital strategies in primary cardiovascular prevention 89
Nitroglycerin-induced activation of monoaminergic trasmission in the rat 89
Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. 89
Calcium homeostasis is dysregulated in Parkinsonian patients with L-DOPA-induced dyskinesias 89
Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. 88
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. 88
Modulation of noradrenergic activity by magnesium salts in panic disorder and neuronal hyperexcitability syndrome 88
Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease 88
Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease 88
Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia 88
Valutazione delle catecolamine plasmatiche: influenza di fattori ambientali e delle procedure di campionamento 87
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 87
Homocysteine and Parkinson's disease: a dangerous liaison? 86
Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease. 86
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease 86
From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries 85
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. 85
Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat 85
The Involvement of Post-Translational Modifications in Alzheimer's Disease 85
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 85
Activation of brain metabolism and fos during limbic seizures: The role of Locus Coeruleus 85
Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson’s disease 85
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 84
Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: New clues from an old model 84
Noninvasive neuromodulation in Parkinson's disease: Neuroplasticity implication and therapeutic perspectives 84
Systemic administration of ephedrine induces Fos protein expression in caudate putamen and subthalamic nucleus of rats. 83
Influence of estrogen modulation on glia activation in a murine model of parkinson's disease 82
Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease 82
Facemasks and face recognition: Potential impact on synaptic plasticity 82
Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. 81
Dopaminergic Modulation of Apoptosis in Human Peripheral Blood Mononuclear Cells: Possible Relevance for Parkinson's Disease 81
A blood-based marker of mitochondrial DNA damage in Parkinson's disease 80
Peripheral levels of BDNF and NGF in primary headaches 80
The Involvement of Post-Translational Modifications in Alzheimer's Disease 80
Single or combined treatment with l-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells 80
Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. 79
Free plasma catecholamine levels in healthy subjects: a basal and dynamic study 78
Potential therapeutic effects of polyphenols in Parkinson's disease: In vivo and in vitro pre-clinical studies 77
Intestinal dysmotility and enteric neurochemical changes following nigrostriatal dopaminergic denervation in the rat: relevance to the gastrointestinal dysfunction associated with Parkinson's disease 76
An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease 76
Totale 10.019
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.298
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.298
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022810 0 2 34 6 4 16 12 43 51 11 122 509
2022/20232.712 302 199 43 236 218 259 0 165 1.184 9 55 42
2023/2024969 121 146 44 56 92 250 35 56 7 27 57 78
2024/20252.833 121 215 66 80 88 152 145 176 645 142 376 627
2025/20266.059 448 400 648 635 733 213 1.300 337 536 429 218 162
2026/2027366 147 219 0 0 0 0 0 0 0 0 0 0
Totale 15.463